The University of Chicago Header Logo

Connection

J. Thistlethwaite to Immunosuppressive Agents

This is a "connection" page, showing publications J. Thistlethwaite has written about Immunosuppressive Agents.
Connection Strength

2.293
  1. Kidney transplantation: graft monitoring and immunosuppression. World J Surg. 2002 Feb; 26(2):185-93.
    View in: PubMed
    Score: 0.142
  2. Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group. Transplantation. 2000 Sep 15; 70(5):784-90.
    View in: PubMed
    Score: 0.130
  3. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation. 1999 Sep 15; 68(5):608-16.
    View in: PubMed
    Score: 0.121
  4. Smooth muscle-specific actin levels in the urine of renal transplant recipients: correlation with cyclosporine or tacrolimus nephrotoxicity. Am J Kidney Dis. 1999 Jul; 34(1):69-84.
    View in: PubMed
    Score: 0.119
  5. Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience. Transplant Proc. 1998 Jun; 30(4):1369-70.
    View in: PubMed
    Score: 0.111
  6. Successful use of tacrolimus for initial rejection episodes after liver transplantation. Transplant Proc. 1998 Jun; 30(4):1407-8.
    View in: PubMed
    Score: 0.111
  7. Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation. Transplant Proc. 1998 Jun; 30(4):1538-40.
    View in: PubMed
    Score: 0.111
  8. Effects of tacrolimus, mycophenolate mofetil, and cyclosporine microemulsion on rejection incidence in synchronous pancreas-kidney transplantation. Transplant Proc. 1998 Mar; 30(2):507-8.
    View in: PubMed
    Score: 0.109
  9. Reversal of accelerated renal allograft rejection with FK 506. Clin Transplant. 1997 Aug; 11(4):251-4.
    View in: PubMed
    Score: 0.104
  10. Tacrolimus treatment of steroid-resistant rejection provides economic advantages compared with OKT3 therapy. Transplant Proc. 1997 Feb-Mar; 29(1-2):1549.
    View in: PubMed
    Score: 0.101
  11. Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. Transplantation. 1996 Oct 15; 62(7):906-10.
    View in: PubMed
    Score: 0.099
  12. Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation. Transplant Proc. 1996 Aug; 28(4):2136-7.
    View in: PubMed
    Score: 0.097
  13. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation. Clin Transplant. 1996 Aug; 10(4):323-32.
    View in: PubMed
    Score: 0.097
  14. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection. Clin Transplant. 1996 Aug; 10(4):389-95.
    View in: PubMed
    Score: 0.097
  15. Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients. Transplant Proc. 1996 Apr; 28(2):1014.
    View in: PubMed
    Score: 0.095
  16. Low-dose anti-CD3 therapy provides long-term graft survival in a Lewis rat to C57BL/6 xeno-islet transplantation model. Transplant Proc. 1994 Apr; 26(2):771-3.
    View in: PubMed
    Score: 0.083
  17. Transplantation and the CD28/CTLA4/B7 pathway. Transplant Proc. 2001 Feb-Mar; 33(1-2):209-11.
    View in: PubMed
    Score: 0.033
  18. Evaluation of pre- and posttransplant donor-specific transfusion/cyclosporine A in non-HLA identical living donor kidney transplant recipients. Cooperative Clinical Trials in Transplantation Research Group. Transplantation. 1999 Oct 27; 68(8):1117-24.
    View in: PubMed
    Score: 0.031
  19. Cutting edge: blockade of the CD28/B7 costimulatory pathway inhibits intestinal allograft rejection mediated by CD4+ but not CD8+ T cells. J Immunol. 1999 Sep 01; 163(5):2358-62.
    View in: PubMed
    Score: 0.030
  20. Liver transplantation in the first three months of life. Transplantation. 1998 Sep 15; 66(5):606-9.
    View in: PubMed
    Score: 0.028
  21. Tacrolimus therapy for refractory acute renal allograft rejection: a 4-year experience with an aggressive approach. Transplant Proc. 1998 Jun; 30(4):1234-5.
    View in: PubMed
    Score: 0.028
  22. Corticosteroid cessation 1 week following renal transplantation using tacrolimus/mycophenolate mofetil based immunosuppression. Transplant Proc. 1998 Jun; 30(4):1378-9.
    View in: PubMed
    Score: 0.028
  23. Cyclosporine versus cyclosporine microemulsion in pediatric liver transplant recipients. Transplant Proc. 1998 Jun; 30(4):1435-6.
    View in: PubMed
    Score: 0.028
  24. Transplantation. JAMA. 1997 Jun 18; 277(23):1902-4.
    View in: PubMed
    Score: 0.026
  25. Tacrolimus therapy for refractory renal allograft rejection: experience with steroid withdrawal. Transplant Proc. 1997 Feb-Mar; 29(1-2):307.
    View in: PubMed
    Score: 0.025
  26. Tacrolimus therapy for refractory acute renal allograft rejection: a prospective multicenter trial. Tacrolimus Kidney Transplantation Rescue Study Group. Transplant Proc. 1996 Dec; 28(6):3163-4.
    View in: PubMed
    Score: 0.025
  27. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplantation. 1996 Sep 15; 62(5):594-9.
    View in: PubMed
    Score: 0.025
  28. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation. 1996 Aug 15; 62(3):370-5.
    View in: PubMed
    Score: 0.024
  29. Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. Transplantation. 1996 May 15; 61(9):1365-9.
    View in: PubMed
    Score: 0.024
  30. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506. Transplant Proc. 1996 Apr; 28(2):998-9.
    View in: PubMed
    Score: 0.024
  31. OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: association with improvement in long-term survival. Kidney Int. 1996 Mar; 49(3):768-72.
    View in: PubMed
    Score: 0.024
  32. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation. 1994 Jun 15; 57(11):1537-43.
    View in: PubMed
    Score: 0.021
  33. Orthotopic auxiliary liver transplantation for Crigler-Najjar syndrome type 1. Lancet. 1993 Sep 25; 342(8874):779-80.
    View in: PubMed
    Score: 0.020
  34. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science. 1992 Aug 07; 257(5071):789-92.
    View in: PubMed
    Score: 0.018
  35. Selective OKT3 induction therapy in adult cadaveric-donor renal transplant recipients. Am J Kidney Dis. 1989 Nov; 14(5 Suppl 2):28-34.
    View in: PubMed
    Score: 0.015
  36. Potent immunosuppression overcomes immunologic high-risk factors in recipients of cadaveric renal allografts. Am Surg. 1987 Jul; 53(7):407-9.
    View in: PubMed
    Score: 0.013
  37. T cell immunofluorescence flow cytometry cross-match results in cadaver donor renal transplantation. Transplant Proc. 1987 Feb; 19(1 Pt 1):722-4.
    View in: PubMed
    Score: 0.013
  38. Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation. 2004 Oct 27; 78(8):1233-6.
    View in: PubMed
    Score: 0.011
  39. The clinical and pathologic implications of plasmacytic infiltrates in percutaneous renal allograft biopsies. Hum Pathol. 2001 Feb; 32(2):205-15.
    View in: PubMed
    Score: 0.008
  40. Role of STAT6 signaling in the induction and long-term maintenance of tolerance mediated by CTLA4-Ig. Transplant Proc. 2001 Feb-Mar; 33(1-2):214-6.
    View in: PubMed
    Score: 0.008
  41. Induction, maintenance, and reversal of streptozotocin-induced insulin-dependent diabetes mellitus in the juvenile cynomolgus monkey (Macaca fascilularis). Transplantation. 1999 Aug 15; 68(3):331-7.
    View in: PubMed
    Score: 0.008
  42. The relationship of untreated borderline infiltrates by the Banff criteria to acute rejection in renal allograft biopsies. J Am Soc Nephrol. 1999 Aug; 10(8):1806-14.
    View in: PubMed
    Score: 0.008
  43. Modified surgical model of paratopic small bowel transplantation in mice. J Surg Res. 1998 Dec; 80(2):188-93.
    View in: PubMed
    Score: 0.007
  44. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation. 1998 Feb 15; 65(3):393-6.
    View in: PubMed
    Score: 0.007
  45. Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children. J Pediatr. 1997 Jul; 131(1 Pt 1):98-104.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.